18:I[40250,["874","static/chunks/874-707bced0679c3297.js","347","static/chunks/347-19b09d9a0639f34d.js","52","static/chunks/52-8655fc43cdf71b68.js","131","static/chunks/131-87dfea644d34aa05.js","6","static/chunks/app/%5Bdomain%5D/%5Blang%5D/%5Bsubpage%5D/%5Bslug%5D/page-889d0c3de5988e3c.js"],"default"] 19:T50e,

Mental health conditions such as PTSD, anxiety and depression affect millions of people worldwide. Yet for more than 30 years, innovation in treatment approaches has been scarce – existing drugs often come with significant side effects and limited efficacy.

Basel-based Synendos Therapeutics is addressing exactly this. With SYT-510, the company is pioneering a breakthrough therapy based on SERI technology. This novel approach restores brain network function holistically by targeting dysregulated neurotransmission across multiple regions and neural circuits. The result? A potentially more tolerable and effective treatment for severe neuropsychiatric disorders.

Since its inception in 2019, Synendos has achieved key milestones: preclinical development is complete, Phase 1 trials are progressing successfully, and exclusive patents strengthen its technology leadership. With the backing of leading venture capital investors and ongoing collaborations with the pharmaceutical industry, the company is now moving into the next phase of clinical development.

The need is clear. In the US alone, the cost of treating PTSD exceeds 230 billion dollars annually – a market in desperate need of better solutions. Synendos' innovation could mark a breakthrough.

1a:T50f,

Basel-based Synendos Therapeutics is addressing exactly this. With SYT-510, the company is pioneering a breakthrough therapy based on SERI technology. This novel a